The content on this site is intended for healthcare professionals only
Dr Aurelio Castrellon speaks to ecancer about targeted therapy for breast cancer.
He says that the main targeted treatments that are now in use against breast cancer are tyrosine kinase inhibitors.
Dr Castrellon mentions that his presentation at ASCO Miami 2021 Symposium covered the results from the PALOMA, MonaLisa and MONARCH trials.
He then explains the results from these trials and their significance in targeted therapy for breast cancer.
He concludes, by mentioning some of the drugs that can be used to treat breast cancer.
Watch the meeting in full by following the links below:
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC
Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
